Literature DB >> 24859533

In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Yunching Chen1, Dong-Yu Gao2, Leaf Huang3.   

Abstract

MicroRNAs (miRNAs), small non-coding RNAs, can regulate post-transcriptional gene expressions and silence a broad set of target genes. miRNAs, aberrantly expressed in cancer cells, play an important role in modulating gene expressions, thereby regulating downstream signaling pathways and affecting cancer formation and progression. Oncogenes or tumor suppressor genes regulated by miRNAs mediate cell cycle progression, metabolism, cell death, angiogenesis, metastasis and immunosuppression in cancer. Recently, miRNAs have emerged as therapeutic targets or tools and biomarkers for diagnosis and therapy monitoring in cancer. Since miRNAs can regulate multiple cancer-related genes simultaneously, using miRNAs as a therapeutic approach plays an important role in cancer therapy. However, one of the major challenges of miRNA-based cancer therapy is to achieve specific, efficient and safe systemic delivery of therapeutic miRNAs in vivo. This review discusses the key challenges to the development of the carriers for miRNA-based therapy and explores current strategies to systemically deliver miRNAs to cancer without induction of toxicity.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Gene delivery; In vivo delivery; Nanotechnology; miRNA

Mesh:

Substances:

Year:  2014        PMID: 24859533      PMCID: PMC5009470          DOI: 10.1016/j.addr.2014.05.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  150 in total

1.  Human microRNA (miR29b) expression controls the amount of branched chain alpha-ketoacid dehydrogenase complex in a cell.

Authors:  Benjamin D Mersey; Peng Jin; Dean J Danner
Journal:  Hum Mol Genet       Date:  2005-10-03       Impact factor: 6.150

2.  Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.

Authors:  Jing Zhang; Lei Miao; Shutao Guo; Yuan Zhang; Lu Zhang; Andrew Satterlee; William Y Kim; Leaf Huang
Journal:  J Control Release       Date:  2014-03-15       Impact factor: 9.776

3.  Emerging therapies in pancreas cancer.

Authors:  Adam Kotowski; Wen W Ma
Journal:  J Gastrointest Oncol       Date:  2011-06

4.  MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

Authors:  Ahmed Fawzy Ibrahim; Ulrike Weirauch; Maren Thomas; Arnold Grünweller; Roland K Hartmann; Achim Aigner
Journal:  Cancer Res       Date:  2011-06-20       Impact factor: 12.701

5.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells.

Authors:  Rajib Ghosh; Lalithya C Singh; Jason M Shohet; Preethi H Gunaratne
Journal:  Biomaterials       Date:  2012-10-27       Impact factor: 12.479

Review 7.  Mesenchymal stem cells in drug/gene delivery: implications for cell therapy.

Authors:  Steven J Greco; Pranela Rameshwar
Journal:  Ther Deliv       Date:  2012-08

8.  Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.

Authors:  Amanda Tivnan; Wayne Shannon Orr; Vladimir Gubala; Robert Nooney; David E Williams; Colette McDonagh; Suzanne Prenter; Harry Harvey; Raquel Domingo-Fernández; Isabella M Bray; Olga Piskareva; Catherine Y Ng; Holger N Lode; Andrew M Davidoff; Raymond L Stallings
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

9.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

Review 10.  Cancer development, progression, and therapy: an epigenetic overview.

Authors:  Sibaji Sarkar; Garrick Horn; Kimberly Moulton; Anuja Oza; Shannon Byler; Shannon Kokolus; McKenna Longacre
Journal:  Int J Mol Sci       Date:  2013-10-21       Impact factor: 5.923

View more
  191 in total

1.  Synthesis and Evaluation of Chloroquine-Containing DMAEMA Copolymers as Efficient Anti-miRNA Delivery Vectors with Improved Endosomal Escape and Antimigratory Activity in Cancer Cells.

Authors:  Ying Xie; Fei Yu; Weimin Tang; Bolutito Oluwole Alade; Zheng-Hong Peng; Yazhe Wang; Jing Li; David Oupický
Journal:  Macromol Biosci       Date:  2017-08-04       Impact factor: 4.979

Review 2.  Progress and problems with the use of suicide genes for targeted cancer therapy.

Authors:  Zahra Karjoo; Xuguang Chen; Arash Hatefi
Journal:  Adv Drug Deliv Rev       Date:  2015-05-22       Impact factor: 15.470

3.  Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy.

Authors:  Ying Xie; Tracy Murray-Stewart; Yazhe Wang; Fei Yu; Jing Li; Laurence J Marton; Robert A Casero; David Oupický
Journal:  J Control Release       Date:  2016-12-23       Impact factor: 9.776

4.  Analysis of the Gap Junction-dependent Transfer of miRNA with 3D-FRAP Microscopy.

Authors:  Heiko Lemcke; Natalia Voronina; Gustav Steinhoff; Robert David
Journal:  J Vis Exp       Date:  2017-06-19       Impact factor: 1.355

5.  Pigmy MicroRNA: surveillance cops in Therapies kingdom.

Authors:  Utpal Bhadra; Pradipta Patra; Jagamohan Chhatai; Manika Pal-Bhadra
Journal:  Mol Med       Date:  2016-09-28       Impact factor: 6.354

Review 6.  An overview of microRNAs.

Authors:  Scott M Hammond
Journal:  Adv Drug Deliv Rev       Date:  2015-05-12       Impact factor: 15.470

Review 7.  MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.

Authors:  Jared A Wallace; Ryan M O'Connell
Journal:  Blood       Date:  2017-07-27       Impact factor: 22.113

8.  MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway.

Authors:  Yuguang Zhao; Dong Pang; Cui Wang; Shijiang Zhong; Shuang Wang
Journal:  Tumour Biol       Date:  2016-03-25

9.  Photocontrolled miR-148b nanoparticles cause apoptosis, inflammation and regression of Ras induced epidermal squamous cell carcinomas in mice.

Authors:  Yiming Liu; Jacob T Bailey; Mohammad Abu-Laban; Shue Li; Cong Chen; Adam B Glick; Daniel J Hayes
Journal:  Biomaterials       Date:  2020-06-22       Impact factor: 12.479

10.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.